RAPT Therapeutics, Inc.
RAPT
Price:
$1.08
Market Cap:
$37.75M
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development o...[Read more]
Industry
Biotechnology
IPO Date
2019-10-31
Stock Exchange
NASDAQ
Ticker
RAPT
PE Ratio
[-0.39]
ROE
[-89.09%]
Current Ratio
[9.90]
Dividend Yield
[0%]
Enterprise Value
[4.97M]
Dividend History
The ROE as of November 2024 (TTM) for RAPT Therapeutics, Inc. (RAPT) is -89.09%
According to RAPT Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -89.09%. This represents a change of 300.63% compared to the average of -22.24% of the last 4 quarters.
RAPT Therapeutics, Inc. (RAPT) Historical ROE (quarterly & annually)
How has RAPT ROE performed in the past?
The mean historical ROE of RAPT Therapeutics, Inc. over the last ten years is -38.40%. The current -89.09% ROE has changed 131.99% with respect to the historical average. Over the past ten years (40 quarters), RAPT's ROE was at its highest in in the March 2019 quarter at 8.69%. The ROE was at its lowest in in the June 2024 quarter at -25.33%.
Average
-38.40%
Median
-50.77%
Minimum
-79.44%
Maximum
46.65%
RAPT Therapeutics, Inc. (RAPT) ROE by Quarter and Year
Discovering the peaks and valleys of RAPT Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 137.84%
Maximum Annual ROE = 46.65%
Minimum Annual Increase = -221.06%
Minimum Annual ROE = -79.44%
| Year | ROE | Change |
|---|---|---|
| 2023 | -79.44% | 137.84% |
| 2022 | -33.40% | -8.74% |
| 2021 | -36.60% | -27.92% |
| 2020 | -50.77% | -13.66% |
| 2019 | -58.80% | 4.11% |
| 2018 | -56.48% | -221.06% |
RAPT Therapeutics, Inc. (RAPT) Average ROE
How has RAPT ROE performed in the past?
The current ROE of RAPT Therapeutics, Inc. (RAPT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-49.81%
5-year avg
-51.80%
10-year avg
-38.40%
RAPT Therapeutics, Inc. (RAPT) ROE vs. Peers
How is RAPT’s ROE compared to its peers?
RAPT Therapeutics, Inc.’s ROE is less than Connect Biopharma Holdings Limited (7.21%), greater than Tyra Biosciences, Inc. (-25.14%), greater than Xilio Therapeutics, Inc. (-214.74%), greater than Mineralys Therapeutics, Inc. (-55.92%), greater than Molecular Partners AG (-39.16%), greater than AN2 Therapeutics, Inc. (-57.63%), greater than Pharvaris N.V. (-38.27%), greater than PepGen Inc. (-60.17%), greater than Monte Rosa Therapeutics, Inc. (-62.68%), greater than Design Therapeutics, Inc. (-18.01%), greater than Werewolf Therapeutics, Inc. (-58.83%), greater than Ikena Oncology, Inc. (-39.59%), greater than Stoke Therapeutics, Inc. (-54.45%), greater than Anebulo Pharmaceuticals, Inc. (-184.40%), greater than PMV Pharmaceuticals, Inc. (-24.20%), greater than Eliem Therapeutics, Inc. (-47.03%), greater than HCW Biologics Inc. (-2516.87%), greater than Relay Therapeutics, Inc. (-45.75%), greater than Pliant Therapeutics, Inc. (-48.91%), greater than Black Diamond Therapeutics, Inc. (-68.08%), greater than Arvinas, Inc. (-50.26%),
| Company | ROE | Market cap |
|---|---|---|
| 7.21% | $55.25M | |
| -25.14% | $801.05M | |
| -214.74% | $39.21M | |
| -55.92% | $621.09M | |
| -39.16% | $216.81M | |
| -57.63% | $39.99M | |
| -38.27% | $1.20B | |
| -60.17% | $143.75M | |
| -62.68% | $521.60M | |
| -18.01% | $318.21M | |
| -58.83% | $84.67M | |
| -39.59% | $82.52M | |
| -54.45% | $605.41M | |
| -184.40% | $37.86M | |
| -24.20% | $83.31M | |
| -47.03% | $342.68M | |
| -2516.87% | $29.12M | |
| -45.75% | $795.07M | |
| -48.91% | $789.88M | |
| -68.08% | $143.73M | |
| -50.26% | $1.78B |
Build a custom stock screener for RAPT Therapeutics, Inc. (RAPT) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like RAPT Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
RAPT Therapeutics, Inc. (RAPT) and other stocks custom spreadsheet templates
The easiest way to analyze a company like RAPT Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is RAPT Therapeutics, Inc.'s ROE?
How is the ROE calculated for RAPT Therapeutics, Inc. (RAPT)?
What is the highest ROE for RAPT Therapeutics, Inc. (RAPT)?
What is the 3-year average ROE for RAPT Therapeutics, Inc. (RAPT)?
What is the 5-year average ROE for RAPT Therapeutics, Inc. (RAPT)?
How does the current ROE for RAPT Therapeutics, Inc. (RAPT) compare to its historical average?